Par-4 binds to topoisomerase 1 and attenuates its DNA relaxation activity

Cancer Research

Volumn 68, Issue 15, 2008, Pages 6190-6198

  Goswami, Anindya ^a   Qiu, Shirley ^a   Dexheimer, Thomas S ^b   Ranganathan, Padhma ^a   Burikhanov, Ravshan ^a   Pommier, Yves ^b   Rangnekar, Vivek M ^a,c,d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; DNA; DNA TOPOISOMERASE; LEUCINE ZIPPER PROTEIN; PROTEINASE ACTIVATED RECEPTOR 4; PRIMER DNA; PROTEASE-ACTIVATED RECEPTOR 4; THROMBIN RECEPTOR;

ARTICLE; CATALYSIS; CELL CYCLE PROGRESSION; CELL TRANSFORMATION; CONTROLLED STUDY; GENE ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; RNA INTERFERENCE; ANIMAL; CELL LINE; CELL STRAIN 3T3; CHEMISTRY; GEL MOBILITY SHIFT ASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; METABOLISM; MOUSE; NUCLEOTIDE SEQUENCE;

ANIMALS; BASE SEQUENCE; CELL LINE, TRANSFORMED; DNA; DNA PRIMERS; DNA TOPOISOMERASES, TYPE I; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LEUCINE ZIPPERS; MICE; NIH 3T3 CELLS; PROTEIN BINDING; RECEPTORS, THROMBIN;

EID: 51049094681     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0831     Document Type: Article

References (45)

1. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001;70:369-413.
2. Koster DA, Palle K, Bot ES, et al. Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature 2007;448:213-7.
3. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
4. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3:430-40.
5. Lee MP, Brown SD, Chen A, Hsieh TS. DNA topoisomerase I is essential in Drosophila melanogaster. Proc Natl Acad Sci U S A 1993;90:6656-60.
6. Morham SG, Kluckman KD, Voulomanos N, Smithies O. Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Mol Cell Biol 1996;16:6804-9.
7. Hwong CL, Chen CY, Shang HF, Hwang J. Increased synthesis and degradation of DNA topoisomerase I during the initial phase of human T lymphocyte proliferation. J Biol Chem 1993;268:18982-6.
8. Tricoli JV, Sahai BM, McCormick PJ, et al. DNA topoisomerase I and II activities during cell proliferation and the cell cycle in cultured mouse embryo fibroblast (C3H 10T1/2) cells. Exp Cell Res 1985;158:1-14.
9. Larsen AK, Gobert C. DNA topoisomerase I in oncology: Dr. Jekyll or Mr. Hyde? Pathol Oncol Res 1999;5:171-8.
10. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-8.
11. Zhu J, Schiestl RH. Human topoisomerase I mediates illegitimate recombination leading to DNA insertion into the ribosomal DNA locus in Saccharomyces cerevisiae. Mol Genet Genom 2004;271:347-58.
12. Laine JP, Opresko PL, Indig FE, et al. Werner protein stimulates topoisomerase I DNA relaxation activity. Cancer Res 2003;63:7136-46.
13. Lebel M, Spillare EA, Harris CC, Leder P. The Werner syndrome gene product co-purifies with the DNA replication complex and interacts with PCNA and topoisomerase I. J Biol Chem 1999;274:37795-9.
14. Sells SF, Wood DP, Jr., Joshi-Barve SS, et al. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 1994;5:457-66.
15. Boghaert ER, Sells SF, Walid AJ, et al. Immunohistochemical analysis of the proapoptotic protein Par-4 in normal rat tissues. Cell Growth Differ 1997;8:881-90.
16. Cook J, Krishnan S, Ananth S, et al. Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 1999;18:1205-8.
17. El-Guendy N, Zhao Y, Gurumurthy S, et al. Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol 2003;23:5516-25.
18. Gurumurthy S, Goswami A, Vasudevan KM, Rangnekar VM. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol 2005;25:1146-61.
19. Qiu G, Ahmed M, Sells SF, et al. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene 1999;18:623-31.
20. Garcia-Cao I, Duran A, Collado M, et al. Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep 2005;6:577-83.
21. Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, et al. Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res 2007;67:1927-34.
22. Goswami A, Burikhanov R, de Thonel A, et al. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell 2005;20:33-44.
23. Zhao Y, Burikhanov R, Qiu S, et al. Cancer resistance in transgenic mice expressing the SAC module of Par-4. Cancer Res 2007;67:9276-85.
24. Nalca A, Qiu SG, El-Guendy N, et al. Oncogenic Ras sensitizes cells to apoptosis by Par-4. J Biol Chem 1999;274:29976-83.
25. Qiu SG, Krishnan S, el-Guendy N, Rangnekar VM. Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformation. Oncogene 1999;18:7115-23.
26. Mo YY, Wang C, Beck W T. A novel nuclear localization signal in human DNA topoisomerase I. J Biol Chem 2000;275:41107-13.
27. Johnstone RW, See RH, Sells SF, et al. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 1996;16:6945-56.
28. Morrell A, Placzek M, Parmley S, et al. Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization. J Med Chem 2007;50:4419-30.
29. Strumberg D, Pommier Y, Paull K, et al. Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. J Med Chem 1999;42:446-57.
30. Merino A, Madden KR, Lane WS, Champoux JJ, Reinberg D. DNA topoisomerase I is involved in both repression and activation of transcription. Nature 1993;365:227-32.
31. Miao ZH, Player A, Shankavaram U, et al. Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res 2007;67:8752-61.
32. Diaz-Meco MT, Lallena MJ, Monjas A, et al. Inactivation of the inhibitory κB protein kinase/nuclear factor κB pathway by Par-4 expression potentiates tumor necrosis factor a-induced apoptosis. J Biol Chem 1999;274:19606-12.
33. Diaz-Meco MT, Municio MM, Frutos S, et al. The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 1996;86:777-86.
34. Cheema SK, Mishra SK, Rangnekar VM, et al. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem 2003;278:19995-20005.
35. Bowen C, Stuart A, Ju JH, et al. NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity. Cancer Res 2007;67:455-64.
36. Karayan L, Riou JF, Seite P, et al. Human ARF protein interacts with topoisomerase I and stimulates its activity. Oncogene 2001;20:836-48.
37. Mao Y, Okada S, Chang LS, Muller MT. p53 dependence of topoisomerase I recruitment in vivo. Cancer Res 2000;60:4538-43.
38. Pommier Y, Jenkins J, Kohlhagen G, Leteurtre F. DNA recombinase activity of eukaryotic DNA topoisomerase I; effects of camptothecin and other inhibitors. Mutat Res 1995;337:135-45.
39. Chakraborty M, Qiu SG, Vasudevan KM, Rangnekar VM. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 2001;61:7255-63.
40. Christensen MO, Barthelmes HU, Boege F, Mielke C. The N-terminal domain anchors human topoisomerase I at fibrillar centers of nucleoli and nucleolar organizer regions of mitotic chromosomes. J Biol Chem 2002;277:35932-8.
41. Sordet O, Khan QA, Plo I, et al. Apoptotic topoisomerase I-DNA complexes induced by staurosporine-mediated oxygen radicals. J Biol Chem 2004;279:50499-504.
42. Sordet O, Khan QA, Pommier Y. Apoptotic topoisomerase I-DNA complexes induced by oxygen radicals and mitochondrial dysfunction. Cell Cycle 2004;3:1095-7.
43. Sordet O, Liao Z, Liu H, et al. Topoisomerase I-DNA complexes contribute to arsenic trioxide-induced apoptosis. J Biol Chem 2004;279:33968-75.
44. Pruitt K, Ulku AS, Frantz K, et al. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem 2005;280:23363-70.
45. Ohira T, Nishio K, Kanzawa F, et al. Hypersensitivity of NIH3T3 cells transformed by H-ras gene to DNA-topoisomerase-I inhibitors. Int J Cancer 1996;67:702-8.